anti-Bevacizumab ELISA Kit (ab237658)
Key features and details
- Sensitivity: 30 ng/ml
- Range: 62 ng/ml - 500 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
製品の概要
-
製品名
anti-Bevacizumab ELISA Kit
Bevacizumab キット 製品一覧 -
検出方法
Colorimetric -
再現性
Intra-Assay(同時再現性) サンプル N 平均値 SD CV% Overall < 15% Inter-Assay(日差再現性) サンプル N 平均値 SD CV% Overall < 15% -
サンプルの種類
Serum, Plasma -
アッセイタイプ
Sandwich (quantitative) -
検出感度
30 ng/ml -
検出範囲
62 ng/ml - 500 ng/ml -
添加回収試験
特定サンプルでの回収試験 サンプルの種類 平均 % 測定範囲 Serum 85% - 115% -
ステップ
Multiple steps standard assay -
種交差性
交差種: Human -
製品の概要
anti-Bevacizumab ELISA Kit (ab237658) is designed to quantify/measure the antibody against Bevacizumab with high specificity and sensitivity in biological matrices.
-
特記事項
This product is manufactured by BioVision, an Abcam company and was previously called E4389 BioSim™ anti-Bevacizumab (Human) ELISA Kit. E4389-100 is the same size as the 96 test size of ab237658.
-
試験プラットフォーム
Microplate
製品の特性
-
保存方法
Store at +4°C. Please refer to protocols. -
内容 96 tests Micro ELISA Plate 1 unit Bevacizumab standard 1 1 x 1ml Bevacizumab standard 2 1 x 1ml Bevacizumab Standard 3 1 x 1ml Bevacizumab Standard 4 1 x 1ml Bevacizumab Standard 5 1 x 1ml Bevacizumab Standard 6 1 x 1ml Bevacizumab Standard 7 1 x 1ml Assay Buffer 1 x 50ml Confirmation Reagent 1 x 12ml Peroxidase Conjugate 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 tablets -
関連性
Bevacizumab is a recombinant human IgG1 monoclonal antibody specific for all human vascular endothelial growth factor-A (VEGF-A) isoforms. The humanized anti-VEGF monoclonal antibody, bevacizumab, has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy. The pharmacokinetic properties of bevacizumab in several species have been previously described and are consistent with a typical humanized monoclonal antibody. It was shown in the literature that the surveillance of circulating concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. Identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Bevacizumab in order to potentially avoid some side effects with a reliable method might be beneficial.
画像
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (0)
ab237658 は論文での使用が確認できていません。